Media Releases - 2005

	Orchid receives USFDA approval for Cefprozil tablets ANDA Product to be launched in the US immediately upon patent expiry
	His Excellency The President of India visits Orchid's state-of-the-art formulations manufacturing complex Addresses scientists and staff on drug discovery opportunity
	Orchid Pharma raises USD 75 million through Global Depositary Receipts (GDRs) and Foreign Currency Convertible Bonds (FCCBs)
	Orchid's Q2 net zooms by 587% Step function increase in turnover and profitability with regulated market thrust
	Orchid enters into exclusive marketing alliance with Mayne Pharma Broad-based global alliance covering select niche injectable products
	Orchid's Ceftriaxone ANDA receives approval from the USFDA Product to be launched in the US today
	Orchid's Q1 FY 2005-06 net profit jumps by 56% Board approves issue of 1:2 Bonus shares
	Orchid receives USFDA approval for Cephalexin ANDA First approval in the oral formulation segment
	Orchid receives GLP certification 5th Company in India to be certified for its R&D expertise
	Orchid registers turnover of Rs 689 crore during 2004-05 Net profit at Rs 31 crore
	Orchid inks development and supply agreement with STADA Pharmaceuticals, Inc. (USA) for six products in the US market
	Orchid's generic formulations facility inspected by USFDA 9 ANDAs reviewed spanning various dosage forms
	Orchid in a new exclusive marketing pact with Alpharma Inc to market oral non-antibiotic formulations in the US and European markets
	Orchid registers turnover of Rs 172 crore during Q3 FY 2004-05 Increases stake in US Discovery JV to 75%

Media Releases - 2004

	Orchid registers turnover of Rs 163.77 crore during Q2 FY 04-05
	Orchid's US discovery JV successfully completes Phase 2(a) trials on its lead anti-diabetic molecule (BLX-1002) | Molecule receives patent clearance from US patent office
	Orchid's generics foray progresses strongly Files 7 Abbreviated New Drug Applications
	Orchid registers turnover of Rs 173.86 crore for Q1 FY 2004-05 Significant progress achieved in the regulated market foray
	Orchid granted Certificate of Suitability (CoS) for Cephradine 8th CoS approval for Orchid
	Orchid extends exclusive marketing pact with Apotex for injectable antibiotics to the Canadian market
	Orchid inks exclusive pact with Par Pharmaceuticals Inc. to market oral cephalosporin formulations in the US market
	Orchid's US discovery JV successfully completes Phase 1(b) clinical trials on its lead anti-diabetic molecule (BLX-1002)
	Orchid files ANDA for Cefazolin finished dosage form
	Orchid's net profit rises 59% during 2003-04
	Orchid's lead anti-diabetic molecule (BLX-1002) successfully completes Phase 1(a) clinical trials
	Orchid granted Certificate of Suitability (CoS) for Cefadroxil Monohydrate
	Orchid to raise up to USD 75 million through Foreign Currency Convertible Bonds
	Orchid granted CoS for Cefotaxime Sodium
	Orchid granted CoS for Cefazolin
	Orchid registers turnover of Rs 171 crore during Q3 FY 2003-04 Q3 net up 126%

Media Releases - 2003

	Orchid’s Aurangabad facility awarded ISO 14001 and OHSAS 18001 certifications
	Orchid’s Cefixime granted CoS approval
	Orchid’s sterile API Cefazolin approved by US FDA
	Orchid’s US JV moves its novel anti-diabetic molecule (BLX-1002) into human clinicals
	Orchid's Q2 net profit surges by 153% Turnover rises by 45% to Rs 162 crore
	Orchid’s API facilities successfully inspected by EDQM & MHRA, UK Development to pave way for quicker approvals of CoS applications this year
	Orchid’s JV manufacturing facility in China commissioned JV to start contributing to the revenue this fiscal
	Orchid's API and formulation facilities receive TGA approval Opens up the key markets of Australia and New Zealand
	Orchid registers a 62% increase in sales turnover (Rs 173 crore) during Q1 FY 2003-04. Profit surges by 160% compared to corresponding quarter last fiscal
	Orchid's US drug discovery JV progresses well on lead anti-diabetic molecule BLX 1002
	Orchid's Cefuroxime Axetil granted CoS approval
	Orchid signs exclusive pact with Apotex to market injectable antibiotics in the US Move to reinforce Orchid’s entry into the US market
	Orchid's net profit rises 210% during 2002-03 Registers higher sales turnover of Rs 541 crore
	Orchid registers turnover of Rs 128.28 crore during Q3 FY 2002-03 Q3 net up 65%
	Orchid’s flagship product Cephalexin approved by USFDA Product also granted Certificate of Suitability (CoS) by the European Directorate

Media Releases - 2002

	Orchid to acquire business of Mano Pharma
	Orchid's flagship product Cephalexin goes through successful USFDA audit
	Orchid's Q2 turnover rises by 19% to Rs 111 crore Significant growth in formulations business
	Orchid ropes in RS Prasad for its US Generics thrust
	Orchid registers a higher sale of Rs 106.84 crore during Q1 FY 2002-03
	Orchid ties up with NCPC to set up a 50:50 joint venture in China
	Orchid establishes a Joint Venture in the US for Drug Discovery
	Orchid declares a dividend of 40%
	Orchid registers sales of Rs 425.52 crore for FY 2001-02
	Orchid's focus on Quality continues..Secures ISO 9001:2000 Certification
	Orchid goes live on SAP ERP
	Orchid aims at niche position in domestic formulations market
	Orchid in major business transformation mode

Media Releases - 2001

	Orchid in joint venture plans to enhance performance..
	Orchid launches SAP ERP Implementation
	Orchid sold 166 MTs of bulk drugs during the first quarter of 2001-02
	Orchid unveils its health portal - Health Orchid
	Orchid ropes in Mr A R Hegde to head its formulations business
	Orchid Allots FCCBs Worth USD 20 Million to IFC.
	Orchid registered a turnover of Rs 371.25 crores for the year 2000-01
	Orchid contributes cash and medicines for Gujarat Earthquake relief
	Orchid registers a turnover of 270.54 Crores.
	Orchid considers Issue of Foreign Currency Convertible Bonds worth US Dollar 30 Million to IFC.